Unapproved colchicine drugs face FDA enforcement
Companies marketing unapproved injectable colchicine drugs used to treat gout have 30 days to stop manufacturing and 180 days to stop shipping the highly toxic intravenous drug, which has caused 23 reported deaths, according to a Feb. 6 FDA statement. Refusal could result in regulatory action, including seizure, injunction or other legal action. The enforcement measure marks the seventh action taken by the agency against companies marketing and selling unapproved drugs since issuing its Compliance Policy Guide (1"The Pink Sheet" June 12, 2006, p. 10). After the 180-day period, all colchicine drugs must have FDA approval to be manufactured or shipped interstate...
You may also be interested in...
FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.